**MINUTES**

**CPIC CONFERENCE CALL**

DATE: April 4, 2019

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping Announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| Guidelines in progress  | Guideline updates in progress:* *CYP2C9/HLA/*phenytoin: Drafting recommendation
* *CYP2D6*/codeine: evidence review underway
* *CYP2C19/*clopidogrel: authorship plan underway

New guidelines in progress: * *CYP2B6*/efavirenz: in review
* *CYP2C19/*PPIs: Drafting recommendation
* *CYP2C9/*celecoxib: Drafting recommendation
* *mtRNR1*/aminoglycosides: authorship plan underway
 | Guideline preparation will continue and Kelly will continue to follow-up. If you or someone you know has expertise in *mtRNR1*/aminoglycosides and would like to be nominated for the writing committee for this CPIC guideline, please email Kelly (Kelly.caudle@stjude.org).  |
| CPIC meeting registration now open | CPIC is planning a CPIC meeting that will be held June 6th and 7th at St. Jude Children’s Research Hospital in Memphis, TN. The preliminary program and registration is available at <https://cpicpgx.org/meetings/>. If you are not staying at the Peabody Hotel or a hotel recommended by CPIC staff, please check with Dawn Bowen (dawn.bowen@stjude.org) or April Blackenship (april.blackenship@stjude.org) about the hotel/airBNB as some of the areas surrounding St. Jude are urban areas and may not be safe. | Kelly will follow-up with more information when available. |
| New CPIC overview presentation available | The dissemination working group recommended that CPIC create a webinar highlighting key points about CPIC and CPIC guidelines. This presentation is now posted on the CPIC website: <https://cpicpgx.org/resources/>.  | n/a |
| AMP-led PGx for warfarin management | Vicky Pratt updated the group on the AMP standardization of clinically relevant pharmacogenetic alleles projects. The major aims for this project are to standardize the alleles that should be included in clinical assays for relevant PGx genes (“Must Test SNP List”), although laboratories could also choose to include additional variants (similar to cystic fibrosis assays). Recommendations will have to be modified as new evidence of clinical utility is developed and new variants are identified. The *CYP2C9* project is complete and is in journal review. The group is now working on recommendations for a warfarin panel. | Vicky will continue to update CPIC members. |
| ClinGen  | Currently ClinGen does not contain pharmacogenetic genes. CPIC has had conversations with ClinGen on how best to represent pharmacogenes on ClinGen, including linking to CPIC guideline content.  | Teri/Mary will continue to update CPIC members. |
| NJ PGx legislature | There is a bill moving through NJ legislature that would require physicians to offer to test a patient for dihydropyrimidine dehydrogenase deficiency prior to chemotherapy, although genetic testing is not specifically mentioned. If you are interested in writing a letter of support, contact Senator Kristin M. Corrado 999 Riverview Drive Suite 350, Totwa, NJ 07512; phone number: (973) 237-1360.  | n/a |
| Proposal for a CPIC Guideline for Rosuvastatin Therapy and *ABCG2* Genotype | Kathy Giacomini and Deanna Brackman presented data supporting an association with rosuvastatin and *ABCG2* genotype and draft clinical recommendation (slides attached with minutes). Members discussed the possibility of adding this gene/drug pair to the *SLCO1B1*/simvastatin guideline update.  | CPIC staff will work to prioritize this gene/drug pair for a guideline |